NDANASALPOWDER
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
BAQSIMI (glucagon) by R-Pharm US is receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. First approved in 2019.
Drug data last refreshed 2d ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BAQSIMI is a nasal powder formulation of glucagon, a rapid-acting antihypoglycemic agent approved in 2019 for emergency treatment of severe hypoglycemia in patients with diabetes. It works by binding to glucagon receptors on hepatic cells, stimulating glycogen breakdown and glucose release into the bloodstream. The nasal delivery route offers a needle-free, user-friendly alternative to injectable glucagon for acute hypoglycemic episodes.
$0.025BPart D
Peak13.3 years to LOEBAQSIMI is at peak commercial maturity with $25M in Part D spending and nearly 50K claims annually, suggesting a stable, focused brand team managing a niche emergency-use indication.
Mechanism of Action
receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect.
Pharmacologic Class:
Antihypoglycemic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Started May 2026
300 enrolled
Obesity or Overweight
Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist
Started Apr 2026
50 enrolled
Laxity; Skin
Glucagon Resistance in Patients With MASLD and T2DM
Started Jan 2026
24 enrolled
Metabolic Associated Fatty Liver DiseaseType 2 Diabetes (T2DM)
Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists
Started Nov 2025
24 enrolled
Wrinkle
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
Started Oct 2025
10 enrolled
glp1 AgonistGene ExpressionSkin Laxity
Worked on BAQSIMI at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.